Vitamin B12 and Folate (5-MTHF): Can You Take Them Together?

Vitamin B12 (as methylcobalamin) and folate (as 5-MTHF) converge at a single enzymatic reaction catalyzed by methionine synthase — one of only two B12-dependent enzymes in the human body. In this reaction, 5-MTHF donates its methyl group to B12, which then transfers it to homocysteine, converting it to methionine. The demethylated folate is regenerated as tetrahydrofolate (THF), which the cell requires for thymidylate synthesis and purine biosynthesis — the building blocks of DNA. This reaction is the only metabolic pathway that can recycle 5-MTHF back to THF, making B12 the sole gatekeeper of folate's functional availability. When B12 is absent, the entire folate pool accumulates as 5-MTHF with no exit route, starving the cell of the THF derivatives needed for DNA replication and repair.

This phenomenon is called the methyl trap hypothesis, and it explains a long-standing clinical paradox: why B12 deficiency produces symptoms of folate deficiency (megaloblastic anemia, impaired DNA synthesis) even when serum folate is adequate or elevated. The trapped 5-MTHF registers as normal on a standard folate blood test, masking the functional deficit. Meanwhile, without B12 to accept the methyl group, homocysteine accumulates — an independent risk factor for cardiovascular disease and adverse pregnancy outcomes. Supplementing folate alone in this scenario can correct the anemia (by providing enough substrate to push through alternative minor pathways) but does nothing to halt the progressive neurological damage caused by B12 deficiency, which includes subacute combined degeneration of the spinal cord. This is why concurrent B12 status must always be confirmed before or during folate supplementation.